Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) -Rationale and design

Katsumi Miyauchi, Takeshi Kimura, Takeshi Morimoto, Yoshihisa Nakagawa, Masakazu Yamagishi, Yukio Ozaki, Takafumi Hiro, Hiroyuki Daida, Masunori Matsuzaki

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: Many trials have shown that 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors reduce the incidence of cardiovascular events and mortality. One method of decreasing the incidence of cardiovascular events could be to reduce the progression of coronary atherosclerosis, and a recent study found that atorvastatin can cause coronary plaque to regress. To generalize this finding, using conventional HMG-CoA reductase inhibitors at many Japanese centers, randomized trials of pitavastatin and atorvastatin will be conducted with patients with acute coronary syndrome (ACS). Methods and Results: Patients with ACS who have undergone successful percutaneous coronary intervention under intravascular ultrasound guidance will be studied. They will be randomly allocated to pitavastatin or atorvastatin groups and followed up for 8-12 months. The primary endpoint will be the percent change in coronary plaque volume, and secondary endpoints will include absolute changes in coronary plaque volume, serum lipid levels and inflammatory markers. The safety profile will also be evaluated. Conclusions: This study will examine the ability of HMG-CoA reductase inhibitors to regress coronary plaque in Japanese patients with ACS and the findings should help to improve the prognosis of such patients and clarify the involved mechanisms.

Original languageEnglish
Pages (from-to)1624-1628
Number of pages5
JournalCirculation Journal
Volume70
Issue number12
DOIs
Publication statusPublished - 01-12-2006

Fingerprint

Acute Coronary Syndrome
Japan
Oxidoreductases
Incidence
Percutaneous Coronary Intervention
Coronary Artery Disease
Lipids
Safety
Mortality
Atorvastatin Calcium
pitavastatin
Serum
glutaryl-coenzyme A

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Miyauchi, K., Kimura, T., Morimoto, T., Nakagawa, Y., Yamagishi, M., Ozaki, Y., ... Matsuzaki, M. (2006). Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) -Rationale and design. Circulation Journal, 70(12), 1624-1628. https://doi.org/10.1253/circj.70.1624
Miyauchi, Katsumi ; Kimura, Takeshi ; Morimoto, Takeshi ; Nakagawa, Yoshihisa ; Yamagishi, Masakazu ; Ozaki, Yukio ; Hiro, Takafumi ; Daida, Hiroyuki ; Matsuzaki, Masunori. / Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) -Rationale and design. In: Circulation Journal. 2006 ; Vol. 70, No. 12. pp. 1624-1628.
@article{b1afe278a7234f0694d14b67c0eb386b,
title = "Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) -Rationale and design",
abstract = "Background: Many trials have shown that 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors reduce the incidence of cardiovascular events and mortality. One method of decreasing the incidence of cardiovascular events could be to reduce the progression of coronary atherosclerosis, and a recent study found that atorvastatin can cause coronary plaque to regress. To generalize this finding, using conventional HMG-CoA reductase inhibitors at many Japanese centers, randomized trials of pitavastatin and atorvastatin will be conducted with patients with acute coronary syndrome (ACS). Methods and Results: Patients with ACS who have undergone successful percutaneous coronary intervention under intravascular ultrasound guidance will be studied. They will be randomly allocated to pitavastatin or atorvastatin groups and followed up for 8-12 months. The primary endpoint will be the percent change in coronary plaque volume, and secondary endpoints will include absolute changes in coronary plaque volume, serum lipid levels and inflammatory markers. The safety profile will also be evaluated. Conclusions: This study will examine the ability of HMG-CoA reductase inhibitors to regress coronary plaque in Japanese patients with ACS and the findings should help to improve the prognosis of such patients and clarify the involved mechanisms.",
author = "Katsumi Miyauchi and Takeshi Kimura and Takeshi Morimoto and Yoshihisa Nakagawa and Masakazu Yamagishi and Yukio Ozaki and Takafumi Hiro and Hiroyuki Daida and Masunori Matsuzaki",
year = "2006",
month = "12",
day = "1",
doi = "10.1253/circj.70.1624",
language = "English",
volume = "70",
pages = "1624--1628",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "12",

}

Miyauchi, K, Kimura, T, Morimoto, T, Nakagawa, Y, Yamagishi, M, Ozaki, Y, Hiro, T, Daida, H & Matsuzaki, M 2006, 'Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) -Rationale and design', Circulation Journal, vol. 70, no. 12, pp. 1624-1628. https://doi.org/10.1253/circj.70.1624

Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) -Rationale and design. / Miyauchi, Katsumi; Kimura, Takeshi; Morimoto, Takeshi; Nakagawa, Yoshihisa; Yamagishi, Masakazu; Ozaki, Yukio; Hiro, Takafumi; Daida, Hiroyuki; Matsuzaki, Masunori.

In: Circulation Journal, Vol. 70, No. 12, 01.12.2006, p. 1624-1628.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) -Rationale and design

AU - Miyauchi, Katsumi

AU - Kimura, Takeshi

AU - Morimoto, Takeshi

AU - Nakagawa, Yoshihisa

AU - Yamagishi, Masakazu

AU - Ozaki, Yukio

AU - Hiro, Takafumi

AU - Daida, Hiroyuki

AU - Matsuzaki, Masunori

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Background: Many trials have shown that 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors reduce the incidence of cardiovascular events and mortality. One method of decreasing the incidence of cardiovascular events could be to reduce the progression of coronary atherosclerosis, and a recent study found that atorvastatin can cause coronary plaque to regress. To generalize this finding, using conventional HMG-CoA reductase inhibitors at many Japanese centers, randomized trials of pitavastatin and atorvastatin will be conducted with patients with acute coronary syndrome (ACS). Methods and Results: Patients with ACS who have undergone successful percutaneous coronary intervention under intravascular ultrasound guidance will be studied. They will be randomly allocated to pitavastatin or atorvastatin groups and followed up for 8-12 months. The primary endpoint will be the percent change in coronary plaque volume, and secondary endpoints will include absolute changes in coronary plaque volume, serum lipid levels and inflammatory markers. The safety profile will also be evaluated. Conclusions: This study will examine the ability of HMG-CoA reductase inhibitors to regress coronary plaque in Japanese patients with ACS and the findings should help to improve the prognosis of such patients and clarify the involved mechanisms.

AB - Background: Many trials have shown that 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors reduce the incidence of cardiovascular events and mortality. One method of decreasing the incidence of cardiovascular events could be to reduce the progression of coronary atherosclerosis, and a recent study found that atorvastatin can cause coronary plaque to regress. To generalize this finding, using conventional HMG-CoA reductase inhibitors at many Japanese centers, randomized trials of pitavastatin and atorvastatin will be conducted with patients with acute coronary syndrome (ACS). Methods and Results: Patients with ACS who have undergone successful percutaneous coronary intervention under intravascular ultrasound guidance will be studied. They will be randomly allocated to pitavastatin or atorvastatin groups and followed up for 8-12 months. The primary endpoint will be the percent change in coronary plaque volume, and secondary endpoints will include absolute changes in coronary plaque volume, serum lipid levels and inflammatory markers. The safety profile will also be evaluated. Conclusions: This study will examine the ability of HMG-CoA reductase inhibitors to regress coronary plaque in Japanese patients with ACS and the findings should help to improve the prognosis of such patients and clarify the involved mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=33751400537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751400537&partnerID=8YFLogxK

U2 - 10.1253/circj.70.1624

DO - 10.1253/circj.70.1624

M3 - Article

C2 - 17127811

AN - SCOPUS:33751400537

VL - 70

SP - 1624

EP - 1628

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 12

ER -